# DeepQure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deepqure

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.deepqure.com/
- Latest round: Series C (Apr 28, 2025)
- Investors on record: 1

## About

DeepQure Inc. is a pioneering medical technology company focused on developing innovative solutions for hypertension treatment, particularly through its flagship HyperQure RDN System, which offers a minimally invasive approach to managing resistant hypertension.DeepQure Inc. specializes in renal denervation technology aimed at treating hypertension. Founded in 2019 in Seoul, South Korea, the company has maintained its focus on advancing hypertension care without notable pivots in strategy. The founder's previous entrepreneurial history is not disclosed. DeepQure has engaged in one significant deal as of April 28, 2025.DeepQure Inc. is focused on addressing the significant global health challenge of hypertension through its innovative HyperQure RDN System. This flagship product is a laparoscopic-based renal denervation (RDN) device designed to provide a minimally invasive non-drug treatment option for hypertension, particularly for patients with resistant hypertension. The device works by ablating nerves in the renal arteries, which is intended to effectively lower blood pressure and reduce the risk of serious complications associated with uncontrolled hypertension. Targeting a client base that includes healthcare providers and hospitals, specifically those in regions with high incidences of hypertension such as North America, Europe, and parts of Asia, DeepQure aims to offer a viable alternative to traditional medication regimens. The partnership with Seoul National University Hospital enhances the company's credibility and operational reach, potentially allowing for the introduction of its products into diverse healthcare markets.DeepQure’s revenue generation model primarily revolves around partnerships with healthcare institutions and direct sales of its HyperQure RDN System. The company engages in transactions with hospitals and clinics that are looking to implement advanced treatments for hypertension, facilitating a direct-to-consumer approach through medical professionals. Specific pricing details are tailored to meet the needs of these institutions, allowing for a flexible transaction structure that could include bulk purchases or service contracts for ongoing support and maintenance of the RDN devices. Given the critical nature of hypertension treatment, DeepQure's offerings are positioned as essential additions to the portfolios of medical facilities seeking to enhance their treatment capabilities. The RDN technology represents a significant advancement in the field, with the potential to generate substantial revenue through both initial sales and subsequent support agreements.In April 2025, DeepQure Inc. raised an undisclosed amount of Series C funding led by returning investor Sui Generis Partners, with participation from other unspecified investors. The company will use the funding to accelerate its clinical strategy in the US and expand into global markets. Plans for new product developments and entry into specific markets are in progress, although details on exact timelines or additional product launches have not been disclosed.

## Funding rounds

- Series C, Apr 28, 2025 — Sui Generis Partners
- Series B, date not disclosed — Sui Generis Partners

## Investors

- Sui Generis Partners (https://capitalatlas.ai/funds/sui-generis-partners) — Series B, Series C